Clinical trials: Blood Purification
Sub-healthy, Hyperlipidemia
The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults
This study investigates whether using Double Filtration Plasmapheresis (DFPP) could improve the overall health of adults through removing inflammatory cytokines, lipids and toxic metal ions from peripheral blood.
- Conditions
- Sub-healthy, Hyperlipidemia, Toxic Metal Ions Accumulation
- Trial name
- NCT06224296
- Testing
- DFPP
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Septic Shock
Blood Purification for the Treatment of Pathogen Associated Shock
This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated…
- Trial name
- PURIFY-RCT (NCT05011656)
- Testing
- Seraph-100 + State of the Art Care, State of the Art Care
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- ExThera Medical Corporation
Burns
Efferon LPS Hemoadsorption in in Patients With Thermal Burns
The aim of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoadsorption using the Efferon® LPS device to reduce the severity of clinical symptoms and to prevent the progression…
- Trial name
- NCT07568132
- Testing
- Efferon LPS
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Efferon JSC
Acute Coronary Syndrome
Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery
The aim of CyTation is to demonstrate intra-operative removal of ticagrelor by CytoSorb® hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB, using platelet reactivity to adenosine…
- Trial name
- CyTation (NCT04625764)
- Testing
- Blood sampling and analysis
- Where
- 4 sites in Germany, Luxembourg
- Volunteers
- 6 people
- Sponsor
- CytoSorbents Europe GmbH
AKI - Acute Kidney Injury, Acute Renal Failure
A Post-Market Clinical Performance and Safety Evaluation of GamCath HighFlow Dolphin Protect Catheter
The goal of this retrospective chart review is to obtain clinical safety and performance data for the GamCath HighFlow Dolphin Protect Catheter in patients with acute kidney injury, acute renal failure, or chronic kidney disease.
- Conditions
- AKI - Acute Kidney Injury, Acute Renal Failure, CKD, ESRD
- Trial name
- NCT05888376
- Testing
- Vascular access catheter to support dialysis or CRRT
- Where
- 2 sites in Poland
- Volunteers
- 76 people
- Sponsor
- Vantive Health LLC
Septic Shock
Continuous Hemodialysis With an Enhanced Middle Molecule Clearance Membrane
This study aims to demonstrate equivalence in terms of molecule removal between continuous hemodialysis using an "enhanced middle molecule clearance" membrane(Ultraflux EMiC2) and continuous hemofiltration using a standard…
- Trial name
- NCT01067313
- Testing
- Dialyzer Ultraflux EMiC2, Dialyzer Ultraflux AV1000S
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Fresenius Medical Care France
Knee Osteoarthritis
Intra Articular Injection of Peripheral Blood Mononuclear Cells for Knee Osteoarthritis
The goal of this Phase II/III, double-blinded, multicenter clinical trial is to assess the clinical efficacy of autologous peripheral blood mononuclear cells (PBMCs) in the management of knee osteoarthritis (KOA).
- Trial name
- PBMC-KOA (NCT07703280)
- Testing
- High-dose PCP-PBMCs injection, Solu-Medrol, Low-dose PCP-PBMCs injection
- Where
- 4 sites in Taiwan
- Volunteers
- 240 people
- Sponsor
- DuoGenic StemCells Corporation (DGSC)
Hemophilia B
IMMUNINE Pre-Treatment Study
The primary objective of this study is to prospectively document the exposure to IMMUNINE and to monitor FIX inhibitors over a period of approximately 20 to 50 exposure days while receiving prophylactic treatment in up to 50…
- Trial name
- NCT01128881
- Testing
- Factor IX Concentrate (purified, virus-inactivated)
- Where
- 18 sites in Argentina, Brazil and 8 more
- Volunteers
- 57 people
- Sponsor
- Baxalta now part of Shire